On this page
TGFBR2
transforming growth factor beta receptor 2
The *TGFBR2* gene provides instructions for making a protein central to cell signalling, influencing processes such as cell growth, division, and differentiation. The *TGFBR2* gene encodes the transforming growth factor-beta (TGF-β) receptor type 2 protein.
TGFBR2 is located on the short (p) arm of chromosome 3, at band 3p24.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The *TGFBR2* gene is responsible for producing the transforming growth factor-beta (TGF-β) receptor type 2. This receptor operates within a crucial cell communication pathway known as the TGF-β pathway, which governs many cellular functions including growth, differentiation, and programmed cell death [PMID:33677353].
The encoded protein relays extracellular signals into the cell, thereby influencing intracellular activities [PMID:33406354]. Dysfunction in *TGFBR2* can lead to various inherited conditions, including certain connective tissue disorders and predispositions to cancer. Its function as a core receptor within the TGF-β pathway is important for maintaining cellular homeostasis and proper development.
What the gene does
The *TGFBR2* gene primarily functions by encoding a receptor protein that transduces signals from transforming growth factor-beta (TGF-β) molecules. This receptor is integrated into the cell membrane. It possesses an extracellular domain for binding TGF-β and an intracellular domain vital for initiating signal cascades.
When TGF-β attaches to the extracellular domain, *TGFBR2* becomes activated. This activation facilitates its interaction with other receptors on the cell surface, forming a complex that triggers signal transduction. This process initiates a cascade of proteins within the TGF-β signalling pathway.
Signals transmitted via this pathway orchestrate diverse cellular responses. These include cell proliferation (growth and division), differentiation into specialised cell types, cellular movement (motility), and apoptosis (controlled cell death). By regulating these fundamental processes, the TGF-β receptor type 2 assists in preventing uncontrolled cellular growth and division, which is essential for maintaining tissue homeostasis and suppressing tumour formation. The protein kinase domain, spanning amino acids 244-544, is crucial for the enzymatic activity necessary for signal transduction.
Video: Genetics 101
Chromosome location
The *TGFBR2* gene is located on chromosome 3, specifically on the short (p) arm at position 24.1, denoted as 3p24.1. The protein produced from this gene comprises 567 amino acids.
Protein structure
The transforming growth factor-beta receptor type 2 protein, which *TGFBR2* encodes, is a transmembrane protein with distinct functional regions. It includes an extracellular domain for ligand binding and an intracellular domain to initiate signalling cascades within the cell. A key functional area is the Protein kinase domain, found from amino acid positions 244-544, which is crucial for its enzymatic activity in phosphorylating downstream signalling molecules.
Further characterisation identifies a region from amino acids 439-567 as sufficient for interaction with the protein Clusterin (CLU). This interaction may modulate TGF-β signalling and other cellular processes.
Key variants
Variations within the *TGFBR2* gene can impact the structure and function of the transforming growth factor-beta receptor type 2 protein. These genetic changes can range from single nucleotide alterations to larger deletions or duplications. The precise effect of a specific variant on protein function and subsequent health outcomes depends on its location within the gene and how it alters protein activity. Some variants may disrupt the protein's ability to bind TGF-β or activate its signalling cascade, leading to aberrant cellular responses.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1067G>C | p.Arg356Pro | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome |
c.1070G>A | p.Gly357Glu | Pathogenic | ★★☆☆ | Loeys-Dietz syndrome 2 |
c.1134G>C | p.Arg378Ser | Pathogenic/Likely pathogenic | ★★☆☆ | Malignant tumor of esophagus |
c.1136A>T | p.Asp379Val | Pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.1178G>A | p.Cys393Tyr | Pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.1240G>C | p.Ala414Pro | Pathogenic/Likely pathogenic | ★★☆☆ | Familial thoracic aortic aneurysm and aortic dissection |
c.1261A>G | p.Thr421Ala | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.1273A>G | p.Met425Val | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome 2 |
c.1301T>A | p.Met434Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Loeys-Dietz syndrome |
c.1336G>A | p.Asp446Asn | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the *TGFBR2* gene are associated with several inherited conditions, primarily affecting connective tissue and cardiovascular health [PMID:33677353]. These conditions include Loeys-Dietz syndrome, which impacts connective tissue throughout the body and is characterised by vascular abnormalities and skeletal deformities. More than 100 mutations in the *TGFBR2* gene have been found to cause Loeys-Dietz syndrome type II.
Another condition linked to *TGFBR2* variants is familial thoracic aortic aneurysm and dissection. This disorder involves the aorta, the body's largest artery, which can become weakened. Several *TGFBR2* variants have been identified in familial thoracic aortic aneurysm and dissection. Knowledge of *TGFBR2* variants aids diagnosis and patient management.
Inheritance pattern
Conditions caused by pathogenic TGFBR2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
In the UK, the *TGFBR2* gene is included in several NHS England Genomic Medicine Service (GMS) approved PanelApp panels. It is listed as 'green' in panels for conditions such as Arthrogryposis, Clefting, Ehlers Danlos syndrome with a likely monogenic cause, Foetal anomalies, and Familial Thoracic aortic aneurysm or dissection (GMS). This 'green' status indicates that strong evidence supports a causal link between variants in *TGFBR2* and these conditions, making it routinely assessed in these contexts.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Maintaining a healthy lifestyle is generally recommended for overall well-being. For individuals with conditions associated with *TGFBR2* gene variants, such as familial thoracic aortic aneurysm and dissection, specific lifestyle adjustments may be advised by healthcare professionals. This can include managing blood pressure, avoiding strenuous activities that place stress on the aorta, and refraining from smoking to help mitigate risks associated with aortic disease. However, these are general health recommendations and individualised advice should always come from a qualified healthcare provider [PMID:22080326].
Supplement considerations
There is currently no conclusive evidence to suggest that specific dietary supplements can prevent or treat conditions associated with variants in the *TGFBR2* gene. While some supplements are marketed for cardiovascular health or connective tissue support, their efficacy in preventing complications related to *TGFBR2* variants has not been scientifically established. Individuals considering any supplements should consult with a healthcare professional to discuss potential benefits, risks, and interactions with other medications.
Frequently asked questions
What is the primary function of the *TGFBR2* gene?
The *TGFBR2* gene provides instructions for making a protein that acts as a receptor for transforming growth factor-beta (TGF-β). This receptor is crucial for transmitting signals into the cell, regulating processes like cell growth, division, and differentiation.
Which conditions are associated with variants in the *TGFBR2* gene?
Variants in *TGFBR2* are associated with conditions primarily affecting connective tissue and the cardiovascular system. These include Loeys-Dietz syndrome and familial thoracic aortic aneurysm and dissection, both of which can have significant health implications.
Is *TGFBR2* involved in cancer?
Yes, the *TGFBR2* gene plays a role in suppressing tumour formation by regulating cell growth and division. Somatic mutations (acquired during life, not inherited) in *TGFBR2* have been linked to an increased risk of various cancers by disrupting this regulatory signalling process.
How does the *TGFBR2* protein work?
The *TGFBR2* protein sits in the cell membrane and binds to TGF-β molecules outside the cell. This binding activates the receptor, allowing it to form a complex with other receptors and initiate a cascade of signals inside the cell, influencing cell behaviour.
Are lifestyle changes important for individuals with *TGFBR2* variants?
For individuals with conditions linked to *TGFBR2* variants, such as aortic aneurysms, healthcare providers may recommend specific lifestyle adjustments. These often include managing blood pressure, avoiding heavy lifting or strenuous exercise, and not smoking, to help minimise disease progression or complications.
References
- Pezzini A, Del Zotto E, Giossi A. Transforming growth factor β signaling perturbation in the Loeys-Dietz syndrome. Current medicinal chemistry. 2012. PMID: 22335518
- Jondeau G, Boileau C. Genetics of thoracic aortic aneurysms. Current atherosclerosis reports. 2012. PMID: 22415348
- Van Hemelrijk C, Renard M, Loeys B. The Loeys-Dietz syndrome: an update for the clinician. Current opinion in cardiology. 2010. PMID: 20838339
- Frederic MY, Hamroun D, Faivre L. A new locus-specific database (LSDB) for mutations in the TGFBR2 gene: UMD-TGFBR2. Human mutation. 2008. PMID: 17935258
- Biswas S, Trobridge P, Romero-Gallo J. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes, chromosomes & cancer. 2008. PMID: 17985359
- Loeys BL, Schwarze U, Holm T. Aneurysm syndromes caused by mutations in the TGF-beta receptor. The New England journal of medicine. 2006. PMID: 16928994
- Loeys BL, Chen J, Neptune ER. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature genetics. 2005. PMID: 15731757
- Pannu H, Fadulu VT, Chang J. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005. PMID: 16027248